3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
4
Other hematologic neoplasm
2
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
Cisplatin
70
Paclitaxel
68
pembrolizumab
65
Carboplatin
61
Irinotecan
59
Injections
53
Gemcitabine
53
Docetaxel
49
Fluorouracil
35
Cyclophosphamide
35
Pemetrexed
34
Oxaliplatin
31
Capecitabine
30
Bevacizumab
29
Leucovorin
27
atezolizumab
23
Nivolumab
23
tislelizumab
19
Etoposide
18
Cetuximab
17
durvalumab
16
Temozolomide
16
Bortezomib
16
alvocidib
15
Topotecan
15
olaparib
14
Sorafenib
14
Rifampin
14
Itraconazole
14
Erlotinib Hydrochloride
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
pegylated granulocyte colony-stimulating factor
×
Other solid neoplasm
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled